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Background and Objectives: Understanding the pathophysiology of respiratory failure
in coronavirus disease 2019 (COVID-19) is indispensable for development of therapeutic
strategies. Since we observed similarities between COVID-19 and interstitial lung disease
in connective tissue disease (CTD-ILD), we investigated features of autoimmunity in
SARS-CoV-2-associated respiratory failure.
Methods: We prospectively enrolled 22 patients with RT-PCR-confirmed SARS-CoV-2
infection and 10 patients with non-COVID-19-associated pneumonia. Full laboratory
testing was performed including autoantibody (AAB; ANA/ENA) screening using indirect
immunofluorescence and immunoblot. Fifteen COVID-19 patients underwent high-
resolution computed tomography. Transbronchial biopsies/autopsy tissue samples for
histopathology and ultrastructural analyses were obtained from 4/3 cases, respectively.
Results: Thirteen (59.1%) patients developed acute respiratory distress syndrome
(ARDS), and five patients (22.7%) died from the disease. ANA titers ≥1:320 and/or
positive ENA immunoblots were detected in 11/13 (84.6%) COVID-19 patients with
ARDS, in 1/9 (11.1%) COVID-19 patients without ARDS (p = 0.002) and in 4/10 (40%)
patients with non-COVID-19-associated pneumonias (p = 0.039). Detection of AABs was
significantly associated with a need for intensive care treatment (83.3 vs. 10%; p = 0.002)
and occurrence of severe complications (75 vs. 20%, p = 0.03). Radiological and
histopathological findings were highly heterogeneous including patterns reminiscent oforg October 2020 | Volume 11 | Article 5875171
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Frontiers in Immunology | www.frontiersin.exacerbating CTD-ILD, while ultrastructural analyses revealed interstitial thickening,
fibroblast activation, and deposition of collagen fibrils.
Conclusions: We are the first to report overlapping clinical, serological, and imaging
features between severe COVID-19 and acute exacerbation of CTD-ILD. Our findings
indicate that autoimmune mechanisms determine both clinical course and long-term
sequelae after SARS-CoV-2 infection, and the presence of autoantibodies might predict
adverse clinical course in COVID-19 patients.Keywords: autoimmunity, connective tissue disease, SARS-CoV-2, coronavirus disease 2019, autoantibodiesINTRODUCTION
Coronavirus disease 2019 (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused
or contributed to hundreds of thousands of deaths and led to
almost complete shutdown of social and economic life in many
countries (1). Based on what is currently known about
epidemiology, COVID-19 is associated with a mortality rate
between 1 and 7% (2). Major cause of death in COVID-19
infections is acute respiratory failure (acute respiratory distress
syndrome, ARDS), but the exact mechanism of how COVID-19
leads to ARDS is unclear. In most reported morphological
analyses, the authors describe diffuse alveolar damage (DAD)
with an early edematous phase followed by hyaline membrane
formation, desquamation of pneumocytes, and an increased
interstitial mononuclear infiltrate in severe SARS-CoV-2
infection (3). In one case, Tian et al. report loose intra-alveolar
fibromyxoid proliferation reminiscent of organizing pneumonia
(OP) (4). Such combined histological patterns of (organizing)
DAD and OP, summarized by some authors under the term
acute fibrinous organizing pneumonia (AFOP), have also been
observed in interstitial lung disease associated with systemic
lupus erythematosus (SLE), dermatomyositis, and progressive
systemic sclerosis (PSS) (5–7). This is of special relevance since
both organizing DAD as well as CTD-ILD may evolve to
pulmonary fibrosis, and long-term effects of COVID-19 are so
far unknown. Only recently, upregulation of fibrosis-associated
gene expression in COVID-19 has been described (8).
Most CTDs are defined by the presence of specific antinuclear
autoantibodies (ANAs), several of which have been identified
and summarized under the historic term extractable nuclear
antibodies (ENAs), such as anticentromer antibodies (CENP-B),
PM-Scl, SS-B/La, Jo-1, and Scl-70 (9). Only recently, the presence
of such autoantibodies has been described in cases of severe
COVID-19, but the exact relevance of this finding remains
unclear (10, 11).
Taken together, since available data suggests histomorphological
as well as pathophysiological similarities between COVID-19-
associated ARDS and lung manifestations of autoimmune disease,
we hypothesized that a dysregulated immune response upon SARS-
CoV-2 infection might show similarities to acute exacerbation of
CTD-ILD which might shed some light on the mechanism of lung
damage in COVID-19.org 2METHODS
In this prospective trial we consecutively included all patients with
positive SARS-CoV-2-RT-PCR (mucosal swab, pharyngeal or
bronchoalveolar lavage) admitted to the Bundeswehrkrankenhaus
(Armed Forces Hospital) Ulm in March and April 2020 after
obtaining informed consent. Suspected cases without RT-PCR-
confirmed SARS-CoV-2 infection were excluded from the study. A
group of 10 patients with non-COVID-19-associated pneumoniae
served as control group for serological analyses (Supplementary
Table 1). Patients or their relatives had given written informed
consent to routine diagnostic procedures (serology, bronchoscopy,
radiology) as well as (partial) autopsy in the case of death,
respectively, as well as to the scientific use of data and tissue
samples in the present study. This project was approved by the
local ethics committee of the University of Ulm (ref. no. 129-20) and
conducted in accordance with the Declaration of Helsinki.
Clinical Characteristics
We collected clinical information from electronic patient files.
Data included disease-related events, preexisting comorbidities,
imaging, treatment approaches (Supplementary Table 2), and
clinical follow-up. The “Berlin definition’’ was used to categorize
ARDS (12). The Horovitz quotient (PaO2/FiO2) was assessed in
all ARDS cases based on arterial blood gas analysis.
ICU Treatment
During ICU treatment, ventilation parameters, duration of
invasive ventilation, catecholamine support, prone positioning,
Murray lung injury score and the need of additional temporary
dialysis were continuously assessed (Supplementary Table 3)
(13). A profitable trial of prone positioning was defined by an
increasing Horovitz quotient of 30 mmHg or more. One entire
trial covered 16 h of sustained prone positioning.
Serology/Laboratory Values
Blood samples for serology and monitoring of laboratory values
were taken at hospital admission and during ward/ICU
treatment, respectively. Laboratory values included possible
predictors of outcome in COVID-19 patients such as
lymphocyte count, fibrinogen, D-dimers, ferritin, lactate
dehydrogenase (LDH), and bilirubin. We also assessed
troponin-T levels as a marker for cardiac events and infection-October 2020 | Volume 11 | Article 587517
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reactive protein (CRP), and procalcitonin (PCT)). Cut-off
values, median, and range for these parameters are
summarized in Supplementary Table 4.
ANA/ANCA/ENA Testing
Initial screenings for ANA and ANCA (p-ANCA, c-ANCA, x-
ANCA, Anti-PR3, Anti-MPO) were performed by IIF using
patient sera on Hep-2 cells and primate liver tissue slides
(ANA) as well as ethanol- and formol-fixed granulocytes and
purified PR-3 and MPO antigens (ANCA) on glass slides
(Euroimmun AG, Lübeck, Germany) according to the
manufacturer’s protocols (14, 15). In all cases, presence of
specific anti-ENA autoantibodies (anti-Sm, anti-SS-A/Ro, anti-
SS-B/La, anti-Scl-70, anti-centromere, anti-Jo1, anti-Mi-2, anti-
U1-RNP, anti-Ro-52, anti-PM-Scl, anti-CNP B, anti-PCNA,
anti-dsDNA, anti-nucleosome, anti-histone, anti-ribosomal P-
protein, anti-AMA-M2) was assessed by semiquantitative
immunoblot (Anti-ENA Profile 3; Euroimmun AG, Lübeck,
Germany) irrespective of the initial screening result. Following
previously published guidelines, ANA titers ≥1:320 with or
without positive ENA immunoblot or ANA titers of 1:100 with
positive ENA immunoblot were regarded as positive (9, 16).
Laboratory testing was performed by investigators who were
blinded to patient status, and in cases with unclear/borderline
results in either ANA screening or ENA subtyping, tests were
repeated on a new sample, and results were verified by an
external reference laboratory. Quality and reliability of ANA/
ANCA/ENA testing in our institution have been evaluated
through regular interlaboratory ring trials.
Imaging
Imaging was performed on a Somatom Force Scanner (Dual
Source Scanner 2*192 slices, Siemens, Erlangen, Germany) in
accordance to the guidelines of the German Radiological Society
and our hospital’s COVID-19 guidelines, using low-dose CT
(computed tomography) with high-pitch technology (17). The
following parameters were used: Tube voltage: 100 kV with tin
filtering, tube current: 96 mAs with tube current modulation. In
two cases examination was performed as a non-contrast
enhanced full-dose protocol because of suspected ILD, in one
case as a contrast-enhanced CT scan to exclude pulmonary
thromboembolism. X-ray examinations were performed at the
respective wards as bed-side X-ray examinations (Mobilett Mira
Max, Siemens, Erlangen, Germany) as a single anterior–posterior
view. The CT images were evaluated according to the Expert
Consensus Statement of the RSNA and classified as typical,
indeterminate, atypical, and negative appearance for COVID-
19 (17, 18).
Histology and Immunohistochemistry
Lung tissue specimens were obtained as transbronchial biopsies
in four cases. In three deceased patients, partial autopsies were
performed, and lung, heart, and liver tissues were sampled
extensively. Specimens were stained with hematoxylin–eosin
(HE), Phosphotungstic-Acid–Hematoxylin (PTAH), Elastica-
van-Gieson (EvG) and Masson-Goldner (MG). Furthermore,Frontiers in Immunology | www.frontiersin.org 3immunohistochemistry for CD3, CD68, CK7, CMV, and EBV
was performed using prediluted antibodies on a VENTANA
benchmark autostainer (Roche Tissue Diagnostics, Mannheim,
Germany) following routine protocols.
Electron Microscopy
Lung, heart, and liver tissues were immersion-fixed with 4%
paraformaldehyde in 0.1 M PBS, pH 7.4. After several time
washing in 0.1 M PBS, tissue was osmicated with 1% OsO4 in
0.1 M cacodylate and dehydrated in increasing ethanol
concentrations. Epon infiltration and flat embedding were
performed following standard procedures. Methylene blue was
used to stain semithin sections of 0.5 µm. Seventy to ninety-
nanometer-thick sections were cut with an Ultracut UCT
ultramicrotome (Fa. Reichert) and stained with 1% aqueous
uranylic acetate and lead citrate. Samples were studied with a
Zeiss EM 109 electron microscope (Fa. Zeiss) coupled to a
Megaview III Soft Imaging System camera analySIS® software
both from Fa. (Soft Imaging System GmbH).
Statistical Methods
Descriptive statistical methods were used to summarize the data.
Medians and interquartile ranges were used to announce results.
Absolute numbers and percentages were employed to represent
categorial variables. Student’s t-test was used for the comparison
of continuous variables, while Chi-Square-Test/Fisher’s test was
used for categorial variables. All statistical analyses were
conducted using GraphPad PRISM 6 (GraphPad Software Inc.,
San Diego, CA, USA). A p-value <0.05 was regarded as
statistically significant.RESULTS
Baseline Clinical Characteristics of the
Study Cohort
Baseline clinical characteristics of SARS-CoV-2 infected patients
are briefly summarized in Table 1, and we show a timeline of the
complete study cohort with all relevant events in Figure 1. Clinical
characteristics of non-COVID-19-associated pneumonia patients
(controls) are summarized in Supplementary Table 1. Median
age at initial diagnosis was 69.0 years (range, 28–88 years). The
majority of patients were male (12/22 cases; 54.5%). Most frequent
preexisting comorbidities were cardiovascular risk factors (13/22,
59.1%) and established cardiovascular disease (10/22, 45.5%).
Preexisting rheumatic disease was present in 2/22 cases (9.1%):
one patient (#16) had rheumatoid factor-positive rheumatoid
arthritis, the other patient (#1) had a history of rheumatic
disease and associated treatment which could not be evaluated
in more detail. Treatment approaches and drug-related toxicities
are summarized in Supplementary Table 2. Bacterial
superinfection was suspected in 10/22 (45.5%) cases by clinical
course, imaging, and laboratory values. Antibiotic treatment
approaches are summarized in Supplementary Table 5. There
was an overall high rate of complications compared to regular
(non-COVID) ARDS patients (Supplementary Table 6). OneOctober 2020 | Volume 11 | Article 587517
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vv-ECMO (veno-venous extracorporeal membrane oxygenation)
was required. After a median follow-up period of 64.5 days (range,
1–81 days), five patients (22.7%) had died from the disease.Frontiers in Immunology | www.frontiersin.org 4ARDS/Non-ARDS Patients
Thirteen of 22 COVID-19 cases (59.1%) and 1/10 patients (10%)
with non-COVID-19-associated pneumonia presented with or








Age n = 22 n = 9 n = 13
years; median (range) 69 (28–88) 57 (28–88) 71 (53–87) 0.044
Sex n = 9 n = 13
Female 10 (45.5%) 8 (88.9%) 2 (15.4%) 0.002
Male 12 (54.5%) 1 (11.1%) 11 (84.6%)
Preexisting diseases n = 22 n = 9 n = 13
0 6 (27.3%) 5 (55.6%) 1 (7.7%) 0.023
≥1 16 (72.7%) 4 (44.4%) 12 (92.3%)
Type of preexisting disease n = 22 n = 9 n = 13
Cardiovascular risk factors1 13 (59.1%) 4 (44.4%) 9 (69.2%) 0.384
Cardiovascular disease2 10 (45.5%) 4 (44.4%) 6 (46.2%) 1
Oncological disease 5 (22.7%) 1 (11.1%) 4 (30.8%) 0.36
Rheumatic disease 2 (9.1%) – 2 (15.4%) 0.494
Duration of symptomatic disease
(after positive SARS-CoV-2 testing)
n = 22 n = 9 n = 13
days; median (range) 15 (1–28) 14 (12–22) 17 (1–28) 0.315
SARS-CoV-2 detection method n = 22 n = 9 n = 13
Mucosal swab 17 (77.3%) 8 (88.9%) 9 (69.2%) 0.36
Pharyngeal lavage 4 (18.2%) 1 (11.1%) 3 (23.1%) 0.616
Bronchoalveolar lavage 1 (4.5%) – 1 (7.7%) 1
Imaging at initial diagnosis n = 22 n = 9 n = 13
Chest X-ray 3 (13.6%) 1 (11.1%) 2 (15.4%) 1
CT scan 15 (68.2%) 4 (44.4%) 11 (84.6%) 0.074
No imaging at initial diagnosis 4 (18.2%) 4 (44.4%) – 0.017
Radiological features at initial
diagnosis (CT Scan)3
n = 15 n = 4 n = 11
Typical 8 (53.3%) 2 (50.0%) 6 (54.5%) 1
Indeterminate 1 (6.7%) – 1 (9.1%) 1
Atypical 2 (13.4%) – 2 (18.2%) 1
Negative for pneumonia 4 (26.7%) 2 (50.0%) 2 (27.3%) 0.517
ICU treatment n = 22 n = 9 n = 13
Yes 11 (50%) – 11 (84.6%) <0.001
No 11 (50%) 9 (100.0%) 2 (15.4%)
Respiration n = 22 n = 9 n = 13
Breathing spontaneously 9 (40.9%) 9 (100.0%) – <0.001
Oxygen support 3 (13.6%) – 3 (23.1%)
Invasive ventilation 10 (45.5%) – 10 (76.9%)
LDH n = 20 n=7 n=13
U/L; median (range) 297 (167–754) 194 (167–254) 365 (248–754) 0.002
C-reactive protein n = 20 n = 7 n = 13
mg/dl; median (range) 7.3 (0.1–42.1) 0.5 (0.1–25.5) 11.7 (2–42.1) 0.038
IL-6 n = 21 n = 8 n = 13
pg/ml; median (range) 61 (2–2205) 12 (2–198) 258 (30–2205) 0.046
ANA/ENA (IIF+IB) n = 22 n = 9 n = 13
ANA/ENA neg.4 10 (45.5%) 8 (88.9%) 2 (15.4%) 0.002
ANA/ENA pos.5 12 (54.5%) 1 (11.1%) 11 (84.6%)
Outcome n = 22 n = 9 n = 13
Follow-up: days; median (range) 64.5 (1–81) 72 (47–75) 59 (1–81) 0.069
Dead from disease 5 (22.7%) – 5 (38.5%) 0.054
Severe complications6 10 (45.5%) 1 (11.1%) 9 (69.2%) 0.012October 2020 | Volume 11 | ArticleANA, antinuclear autoantibody; ARDS, acute respiratory distress syndrome; CT, computed tomography; ENA, extractable nuclear antigen; IB, immunoblot; IIF, indirect
immunofluorescence; IL-6, interleukin 6; LDH, lactate dehydrogenase; na, not applicable; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
1diabetes mellitus, dyslipidemia, arterial hypertension, obesity, nicotine abuse; 2coronary disease, post-myocardial infarction, peripheral arterial vaso-occlusive disease, post-stroke,
atherosclerosis; 3Radiological features have been classified referring to Simpson et al., Radiology: Cardiothoracic Imaging 2.2 (2020): e200152; 4ANA/ENA negative: ANA titer <1:320 and
negative ENA immunoblot; 5ANA/ENA positive: ANA titer ≥1:320 and/or positive ENA immunoblot; 6Severe complications are summarized in Supplementary Table 5.
Significant results (p < 0.05) are highlighted in bold.587517
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Frontiers in Immunology | www.frontiersin.org 5intensive care unit (ICU) treatment was required in 11/22 (50%)
of COVID-19 patients, and one patient with non-COVID-19-
associated pneumonia. COVID-19 patients who developed
ARDS were significantly older, and most of them were male
(p = 0.044 and p = 0.002, Table 1). Furthermore, these patients
presented with more preexisting comorbidities (p = 0.023).
ARDS was significantly associated with ICU treatment,
occurrence of severe complications and (invasive) ventilation
in COVID-19 positive patients (p < 0.001, p = 0.012 and p <
0.001, respectively). The Murray lung injury score was calculated
for all patients who underwent invasive ventilation and revealed
moderate or severe ARDS in 8/10 cases (80.0%) (13). All five
COVID-19-associated deaths occurred in the ARDS group.
Laboratory values for LDH, CRP, and IL-6 were significantly
higher in the group of COVID-19-positive patients who
developed ARDS compared to COVID-19 patients with mild
clinical course. However, LDH, CRP, and IL-6 values were not
significantly different between COVID-19 ARDS patients and
patients with non-COVID-19-associated pneumonia (each p >
0.05, Table 1 and Supplementary Table 1). Initial ANA
screening by IIF showed titers ≥1:100 in all COVID-19 ARDS
patients (100%) but in 4/9 (44.4%) COVID-19 patients without
ARDS. Among the group of non-COVID-19-associated
pneumonias, the initial ANA screening by IIF showed titers
≥1:100 in 7/10 patients (70%). ANCA screening was completely
negative in all investigated COVID-19 cases but positive in 1/10
patients (10%) with non-COVID-19-associated pneumonia.
Specific autoantibodies could be detected by ENA immunoblot
in 6/12 COVID-19 ARDS patients (50%) but in 1/9 COVID-19
non-ARDS patients (11.1%) and 2/10 patients (20%) with non-
COVID-19-associated pneumonia. One patient from the ARDS
group (#9, ANA titer 1:1000) showed borderline positivity for
anti-RNA polymerase III (RP155) autoantibodies only after
reference laboratory testing and was therefore classified as
negative. The distribution and type of ANA/ENA among the
different subgroups are shown in Figure 2A, while representative
images of IIF and IB are shown in Figure 2B. PM-Scl was the
most commonly detected autoantibody (3/7 cases) and could
only be detected in the COVID-19 ARDS group.
Taken together, applying established diagnostic criteria for
ANA/ENA screening as described above (16), 11/13 ARDS
patients (84.6%) and 1/11 non-ARDS patients (11.1%) were
classified as ANA-positive (p = 0.002), while 4/10 (40%) of
non-COVID-19-associated pneumonia patients were classified
as positive (p = 0.039). Of the two COVID-19 patients with a
history of rheumatic disease (#1 and 16), one patient (#1) showed
high ANA titer in IIF (1:1000), while the other patient (#16) had
detectable anti-Nucleosome/anti-dsDNA antibodies.ANA and Clinical Course in
COVID-19 Patients
Detection of ANA was associated with higher age and male sex,
although not significant. ANA positivity, however, was
associated with a necessity of assisted/invasive ventilation, ICU
treatment (both p = 0.002) and occurrence of severe
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ANAs. While there were no significant differences in serum
levels of CRP and IL-6, LDH levels were significantly higher in
the ANA+ group (p = 0.005). The association between ANA
status and disease-specific survival did not reach statistical
significance (p = 0.054) (Table 2).
Imaging, Histopathology, and
Ultrastructural Analyses
“Typical” radiologic COVID-19 patterns were found in 53.3% of
patients (ARDS: 54.4%/non-ARDS: 50%). These included
ground glass opacities (all “typical” cases), consolidation and
(C)OP-like pattern (Figure 3). Atypical/negative patterns were
found in 45.6% of ARDS patients and 50% of non-ARDS
patients. Bronchoscopy with transbronchial biopsy (TBB) was
performed in four patients (cases #1, 8, 13 and 16) before (#8)
and after (#1, 13, 16) an established diagnosis of COVID-19,
respectively (Figure 1). From three of these patients (#1, 8, 13),
additional post-mortem tissue samples were obtained during a
partial autopsy procedure. In all samples, we observed reactive
pneumocyte changes (“Napoleon hat sign”) consistent with viral
infection (Figure 4). However, there was a marked variance in
the histologic appearance between different patients, between
TBB and autopsy samples from the same patient and between
autopsy samples from different regions of the lung. In addition toFrontiers in Immunology | www.frontiersin.org 6hyaline membrane formation consistent with diffuse alveolar
damage (classic DAD), there was also early septal thickening and
intra-alveolar fibrinous plug formation with partial fibromyxoid
change, reminiscent of acute fibrinous organizing pneumonia
(AFOP) (#1, Figure 4A). Ultrastructural analyses of tissue
samples from the same patient showed widening of alveolar
septa with activated fibroblasts and early deposition of fine
collagen fibrils. In patient #13, where biopsies were obtained
on day 23 after initial diagnosis, there was a pattern of organizing
DAD with parenchymal collapse and entrapment of fibrin
(Figure 4B). Tissue samples from autopsy from the same
patient showed areas of beginning, patchy fibrosis with a
foreshadowing of honeycombing. In all autopsy samples, there
was capillary congestion with formation of microthrombi
especially in late-stage disease (Supplementary Figure 1).DISCUSSION
In the present study, we found overlapping serological, clinical,
radiologic, and histopathological features of severe COVID-19
and lung manifestation of autoimmune disease (CTD-ILD). We
show that presence of ANAs is significantly associated with the
development of ARDS, necessity for ICU treatment and invasive
ventilation as well as occurrence of severe complications in theseA
B
FIGURE 2 | (A) Heatmap showing the distribution and subtypes of autoantibodies in the group of COVID-19 patients with ARDS (left), COVID-19 patients without
development of ARDS (center), and non-COVID-19 pneumonia patients (right; clinical data of the non-COVID-19 pneumonia controls are summarized in
Supplementary Table 6). (B) IIF image (left) with fine granular/nucleolar staining pattern and clearly visible “rings and rods” (arrowhead in high magnification inset)
(patient #9). Right: positive ENA immunoblot for Scl-70 (patient #13).October 2020 | Volume 11 | Article 587517
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presented with or developed ARDS had detectable autoantibodies.
With respect to baseline clinical characteristics, the investigated
cohort is comparable to previous reports (2, 19). Our result of
autoantibodies in patients with severe COVD-19 is in line with
first results from other groups (10, 11, 20); however, we are the
first to put this observation into context with clinical, imaging, and
histopathology findings. Furthermore, we confirm the association
between higher age, male sex, and elevated LDH with severe
course of COVID-19 in line with literature data (19). Given the
fact that only hospitalized patients were included, it is not
surprising that the mortality rate (22.7%) was higher compared
to the general population.
Imaging and histopathological data in the present and in
previous studies show that presentation of COVID-19 in the
lung is heterogeneous and evolves over time (4, 21–23). Overall
diversity of these changes, including (organizing) diffuse alveolar
damage, fibromyxoid plugging and interstitial thickening are
reminiscent of exacerbation of CTD (24, 25). However, it has to
be clearly acknowledged that the histopathological spectrum of
virus-induced DAD is wide and also includes findings that have
recently been described to be specific for COVID-19, such as
endothelialitis and (micro-)thrombotic events. Our finding that
significant ANA titers and/or detection of specific
autoantibodies are found in most patients who develop ARDS
raises the question if there is a comparable mechanism of lungFrontiers in Immunology | www.frontiersin.org 7damage between SARS-CoV-2 infection and exacerbating
autoimmune disease. In 4/6 COVID-19 patients with specific
ENAs who developed ARDS, detected autoantibodies were anti-
PM-Scl or anti-Scl-70; if the borderline positivity for RP155 in
patient #9 was included, 5/6 specific ENAs in our cohort would
be associated with a form of sclerosing CTD, as these
autoantibodies (as well as similar HR-CT) patterns have
previously been described in dermatomyositis, (progressive)
systemic sclerosis and CTD-overlap syndromes (26, 27). Of
note, a significant proportion of anti-PM-Scl-/anti-Scl-70-
positive patients develop pulmonary fibrosis, raising the
question of long-term effects of severe COVID-19 in these
patients (28). The possibility of progressively evolving fibrosis
would be supported by our findings from histopathology and
electron microscopy, where we observed organization and
pseudo-honeycombing as well as interstitial fibroblast
activation with collagen deposition. Another parallel between
CTDs and COVID-19 are the vasculitis-like changes, vascular
dysfunction or microangiopathies that have been described in a
subset of patients (29–31). While thromboembolic
complications occurred in only two patients in our cohort
(both ANA-positive), it would be of great interest to screen
patients with more widespread vascular or cutaneous
involvement for the presence of ANA. ANCA screening,
however, was completely negative in our cohort of COVID-






Age n = 10 n = 12
years; median (range) 63 (28–88) 70 (53–84) 0.17
Sex n = 10 n = 12
Female 7 (70%) 3 (25%) 0.084
Male 3 (30%) 9 (75%)
Respiration n = 10 n = 12
Breathing spontaneously 8 (80%) 1 (8.3%) 0.002
Oxygen support 1 (10%) 2 (16.7%)
Invasive ventilation (IV) 1 (10%) 9 (75%)
Duration of IV n = 1 n = 9
days; median (range) 5 24 (5–39) na
Treatment n = 10 n = 12
peripheral ward 9 (90%) 2 (16.7%) 0.002
ICU 1 (10%) 10 (83.3%)
Radiological features (CT)3 n = 6 n = 9
Typical appearance 3 (50.0%) 5 (55.6%) 1
Indeterminate/Atypical/Negative 3 (50.0%) 4 (44.4%)
LDH n = 8 n = 12
U/L; median (range) 215 (167–348) 374 (248–754) 0.005
CRP n = 8 n = 12
mg/dl; median (range) 1.1 (0.1–42.1) 11.3 (1–27.6) 0.445
IL-6 n = 9 n = 12
pg/ml; median (range) 16 (2–2,205) 213 (10–2,093) 0.463
Outcome n = 10 n = 12
Follow-up; days; median (range) 69 (7–75) 62 (1–81) 0.376
Dead from disease 1 (10%) 4 (33.3%) 0.323
Severe complications4 2 (20%) 9 (75%) 0.03October 2020 | Volume 11 | ArticleANA, antinuclear antibody; ARDS, acute respiratory distress syndrome; CRP, C-reactive protein; ICU, intensive care unit; IL-6, interleukin 6; na, not applicable.
1ANA/ENA negative: ANA titer <1:320 and negative ENA immunoblot; 2ANA/ENA positive: ANA titer ≥1:320 and/or positive ENA immunoblot; 3Radiological features have been classified
referring to Simpson et al., Radiology: Cardiothoracic Imaging 2.2 (2020): e200152; 4Severe complications are summarized in Supplementary Table 5.
Significant results (p < 0.05) are highlighted in bold.587517
Gagiannis et al. Autoimmune Features in COVID-19-Induced Respiratory FailureSince it is well-known that ANA screening can be false
positive in severely ill patients or patients who undergo ICU
treatment, a possible epiphenomenon has to be discussed very
frankly. According to a recent publication, a there is no cross-Frontiers in Immunology | www.frontiersin.org 8reactivity between anti-SARS-CoV-2 IgG/IgM and CTD-
associated autoantibodies (32). However, to enhance test
validity in the present study, we a) doubled the recommended




FIGURE 3 | Imaging. (A) Axial thin-section unenhanced CT scan of a 69-year-old woman (patient #1, ANA 1:1,000; see Figure 4A for histology) 12 days after
admission with later-stage disease. Mixed image with diffuse ground-glass opacities (GGOs) and subpleural and peribronchial consolidations with positive
aerobrochogram resembling organizing pneumonia. Additionally, anteriorly accentuated irregular subpleural consolidations with partially left-out subpleural space.
(B) Axial thin-section unenhanced CT scan of a 80 year-old male (patient #8; ANA 1:100), imaged for suspected interstitial lung disease (ILD). Images show right-
sided dominant fibrotic changes in the periphery, with partially sparing of the subpleural space, resembling a NSIP-like pattern. Minimal ground-glass-opacities
(GGOs) in the left subpleural space. (C) Axial thin-section unenhanced CT scans of a 66-year-old female (patient #16, ANA 1:100, anti-Nucleosome/anti-dsDNA
positive). Left image was obtained on the day of hospitalization with a typical sign of a lobar pneumonia of the right lower lobe. Right image (day 10 after admission)
shows bilateral ground glass opacities and consolidations, mainly on the left lower lobe and the middle lobe. The left lower lobe is properly aerated. Additionally,
bilateral pleural effusions are detectable. (D) Axial thin-section unenhanced CT scans of a 58-year-old male (patient #13, ANA 1:100, anti-Scl-70 positive; see Figure
4B for histology) 4 weeks after onset of the disease and ECMO therapy. In addition to diffuse ground glass opacities, a mixture of bronchiectasis, cysts and air-
trapping is evident. Additional pneumothorax and mediastinal emphysema are visible.October 2020 | Volume 11 | Article 587517
Gagiannis et al. Autoimmune Features in COVID-19-Induced Respiratory Failureperformed additional immunoblot for specific ENA in all
patients, thus adding an independent methodological approach
combining high sensitivity and specificity (16, 33). Moreover, we
included a non-COVID-19 pneumonia control group in which
ANA titers ≥ 1:320 could be detected in two patients. Specific
autoantibodies against AMA-M2 (associated with primary
biliary cirrhosis) and Ro52 (associated with SLE) were detected
in two additional patients. Laboratory values in the pneumonia
control group (LDH, CRP, IL-6) were not significantly different
compared to COVID-19 ARDS cases. While it is conceivable that
ANA titers rise and specific autoantibodies may appear in
severely ill patients in general, we think that the observed
clustering of high ANA titers with specific, sclerosis-associated
autoantibodies in the COVID-19 ARDS group is reliable, raising
the question of how these autoantibodies arise in the context of
SARS-CoV-2 infection.
A recent preprint suggests significant extrafollicular B cell
activation with an excessive production of antibody-secreting
cells (ASCs) in critically ill SARS-CoV-2 patients (34). This
mechanism is highly similar to the development and progression
of SLE, and these ASC might represent a possible source of the
autoantibodies we report here (35, 36). We do not assume that
these autoantibodies were already present in predisposed patients
prior to infection, because only two patients in our cohort had any
clinical history of rheumatic or autoimmune disease. However, in
light of our results, there are interesting parallels between the
reported epidemiology of severe COVID-19 and the presence of
autoantibodies in the general population. Autoantibody titers
above 1:80 and 1:160 can be detected in 13.3 and 5% of
otherwise healthy individuals (37), reflecting reportedFrontiers in Immunology | www.frontiersin.org 9proportions of severe (14%) and critical (5%) course of COVID-
19 (38). Preliminary reports from the U.S. suggest that the COVID-
19-associated death rate among African Americans is significantly
higher compared to the general population (39), while at the same
time ANA titers in African Americans exceed those of Americans
with another ethnic background (40). It would be interesting to
screen patients for class I and class II major histocompatibility
complex antigens to see whether it is possible to identify patients
with an enhanced risk for development of autoantibodies and
severe course of the disease.
There is an ongoing debate with regard to a possible
dysregulation of the immune system by SARS-CoV-2, and it
has been discussed whether anti-inflammatory drugs might be
beneficial to prevent potentially harmful hyperinflammation
(41). Our hypothesis of SARS-CoV-2-induced immune
dysregulation closely correlates with results from the Wuhan
cohort reported by Wu et al., in which methylprednisolone
treatment was associated with a more favorable outcome
among the patients who had already developed ARDS (19). A
recent report from Japan described high anti-SSA/Ro antibody
titers in two patients with severe COVID-19 pneumonia, one of
which responded well to corticosteroid therapy (42). Moreover,
first results from the UK RECOVERY trial (EudraCT 2020-
001113-21, press release from Oxford University on June 16,
2020) indicate a significant benefit for dexamethasone, a drug
that is also in use for the treatment of SSc, in mechanically
ventilated patients. It would furthermore be interesting to
evaluate if patients with SLE-like ANA pattern (anti-ds-DNA)
profit from hydroxychloroquine, while patients with an SSc-like
ANA pattern (anti-Scl-70, anti-CENP) might respond toA
B
FIGURE 4 | Histopathological and ultrastructural assessment. (A) Transbronchial biopsies (“Bx”, left) in a 69-year-old woman (patient #1, ANA 1:1,000; see Figure
3A for imaging) 13 days after admission shows septal thickening without fibrinous exudate. Tissue samples from the autopsy (“A”) of the same patient with reactive
pneumocyte changes (“Napoleon hat sign”, arrowhead), ball-like fibrin (yellow circle) and alveoli with plug-like fibromyxoid organization (right). Electron microscopy
shows widening of alveolar septa with activated fibroblasts (asterisk) and deposition of collagen (silvery filaments in inter-alveolar septum). (B) Transbronchial biopsies
in a 58-year-old man (patient #13, ANA 1:100, positive for Scl-70; see Figure 3D for imaging) show alveolar fibromyxoid plugs with entrapment of fibrin (“Bx”, left;
arrowhead). Other areas from the same sample show parenchymal collapse with granulation tissue around residual fibrin (yellow circle). CK7 immunohistochemistry
highlights pneumocyte lining of collapsed alveoli. Right: tissue samples from autopsy (“A”) show interstitial fibroblast activation (arrowhead) and pseudo-
honeycombing. Scale bar, 100 µm.October 2020 | Volume 11 | Article 587517
Gagiannis et al. Autoimmune Features in COVID-19-Induced Respiratory Failurecyclophosphamide. In line with that, one case report described a
mild clinical course of COVID-19 in patient with established
anti-Scl-70-positive SSc under treatment with the anti-
interleukin (IL) 6 receptor blocker tocilizumab (43). The
correct timing and dosing for any immunosuppressive or anti-
fibrotic treatment approach in response to a viral infection
however remains unclear.
Possible limitations of this study include its limited sample
size and the lack of randomization. A further limitation of this
study is the possibility of selection bias, which could not be ruled
out on account of the study design.
Our observation of CTD-associated autoantibodies together
with the CTD-like radiologic and histopathologic lung findings
in severe cases of COVID-19 point towards a possible
dysregulation of the immune response upon SARS-CoV-2
infection that might fuel organizing pneumonia and trigger
interstitial fibrosis, with deleterious effects on the functional
outcome in long-term survivors. Early detection of the
reported autoantibodies might identify patients who profit
from immunosuppressive and/or anti-fibrotic therapy to
prevent the development of respiratory failure and fibrosis in
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